# Developmental Therapeutics Program

## One Dose Mean Graph

| | | |
|---|---|---|
| **NSC:** 777489 / 1 | **Conc:** 1.00E-5 Molar | **Test Date:** Oct 28, 2013 |
| **Experiment ID:** 1310OS90 | | **Report Date:** Feb 07, 2014 |

| Panel/Cell Line | Growth Percent |
|---|---|
| Leukemia | |
| CCRF-CEM | 92.91 |
| HL-60(TB) | 102.51 |
| K-562 | 83.92 |
| MOLT-4 | 90.17 |
| RPMI-8226 | 100.54 |
| SR | 82.35 |
| Non-Small Cell Lung Cancer | |
| A549/ATCC | 94.71 |
| HOP-62 | 99.66 |
| HOP-92 | 114.60 |
| NCI-H226 | 95.44 |
| NCI-H23 | 100.35 |
| NCI-H322M | 112.06 |
| NCI-H460 | 104.65 |
| NCI-H522 | 99.33 |
| Colon Cancer | |
| COLO 205 | 113.22 |
| HCC-2998 | 106.38 |
| HCT-116 | 92.90 |
| HCT-15 | 91.24 |
| HT29 | 104.12 |
| KM12 | 102.60 |
| SW-620 | 97.45 |
| CNS Cancer | |
| SF-268 | 97.11 |
| SF-295 | 93.14 |
| SF-539 | 85.45 |
| SNB-19 | 96.43 |
| SNB-75 | 87.87 |
| U251 | 93.07 |
| Melanoma | |
| LOX IMVI | 86.54 |
| MALME-3M | 102.67 |
| MDA-MB-435 | 92.43 |
| SK-MEL-2 | 104.06 |
| SK-MEL-28 | 120.80 |
| SK-MEL-5 | 99.03 |
| UACC-257 | 82.38 |
| UACC-62 | 93.90 |
| Ovarian Cancer | |
| IGROV1 | 109.19 |
| OVCAR-3 | 99.65 |
| OVCAR-4 | 106.18 |
| OVCAR-5 | 117.73 |
| OVCAR-8 | 97.18 |
| NCI/ADR-RES | 106.75 |
| SK-OV-3 | 97.41 |
| Renal Cancer | |
| 786-0 | 88.20 |
| A498 | 54.65 |
| ACHN | 106.29 |
| CAKI-1 | 96.76 |
| RXF 393 | 95.43 |
| SN12C | 98.57 |
| TK-10 | 111.98 |
| UO-31 | 103.90 |
| Prostate Cancer | |
| PC-3 | 97.62 |
| DU-145 | 102.75 |
| Breast Cancer | |
| MCF7 | 80.10 |
| MDA-MB-231/ATCC | 79.93 |
| HS 578T | 97.81 |
| MDA-MB-468 | 88.11 |
| Mean | 97.36 |
| Delta | 42.71 |
| Range | 66.15 |

**Mean Growth Percent - Growth Percent**